Cargando…

Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy

Low back pain (LBP) is a serious medical condition that affects a large percentage of the population worldwide. One cause of LBP is disc degeneration (DD), which is characterized by progressive breakdown of the disc and an inflamed disc environment. Current treatment options for patients with sympto...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverman, Lara Ionescu, Heaton, Will, Farhang, Niloofar, Saxon, Lindsey Hart, Dulatova, Galina, Rodriguez-Granrose, Daniel, Flanagan, Flagg, Foley, Kevin T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772215/
https://www.ncbi.nlm.nih.gov/pubmed/33392242
http://dx.doi.org/10.3389/fsurg.2020.554382
_version_ 1783629829737807872
author Silverman, Lara Ionescu
Heaton, Will
Farhang, Niloofar
Saxon, Lindsey Hart
Dulatova, Galina
Rodriguez-Granrose, Daniel
Flanagan, Flagg
Foley, Kevin T.
author_facet Silverman, Lara Ionescu
Heaton, Will
Farhang, Niloofar
Saxon, Lindsey Hart
Dulatova, Galina
Rodriguez-Granrose, Daniel
Flanagan, Flagg
Foley, Kevin T.
author_sort Silverman, Lara Ionescu
collection PubMed
description Low back pain (LBP) is a serious medical condition that affects a large percentage of the population worldwide. One cause of LBP is disc degeneration (DD), which is characterized by progressive breakdown of the disc and an inflamed disc environment. Current treatment options for patients with symptomatic DD are limited and are often unsuccessful, so many patients turn to prescription opioids for pain management in a time when opioid usage, addiction, and drug-related deaths are at an all-time high. In this paper, we discuss the etiology of lumbar DD and currently available treatments, as well as the potential for cell therapy to offer a biologic, non-opioid alternative to patients suffering from the condition. Finally, we present an overview of an investigational cell therapy called IDCT (Injectable Discogenic Cell Therapy), which is currently under evaluation in multiple double-blind clinical trials overseen by major regulatory agencies. The active ingredient in IDCT is a novel allogeneic cell population known as Discogenic Cells. These cells, which are derived from intervertebral disc tissue, have been shown to possess both regenerative and immunomodulatory properties. Cell therapies have unique properties that may ultimately lead to decreased pain and improved function, as well as curb the numbers of patients pursuing opioids. Their efficacy is best assessed in rigorous double-blinded and placebo-controlled clinical studies.
format Online
Article
Text
id pubmed-7772215
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77722152020-12-31 Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy Silverman, Lara Ionescu Heaton, Will Farhang, Niloofar Saxon, Lindsey Hart Dulatova, Galina Rodriguez-Granrose, Daniel Flanagan, Flagg Foley, Kevin T. Front Surg Surgery Low back pain (LBP) is a serious medical condition that affects a large percentage of the population worldwide. One cause of LBP is disc degeneration (DD), which is characterized by progressive breakdown of the disc and an inflamed disc environment. Current treatment options for patients with symptomatic DD are limited and are often unsuccessful, so many patients turn to prescription opioids for pain management in a time when opioid usage, addiction, and drug-related deaths are at an all-time high. In this paper, we discuss the etiology of lumbar DD and currently available treatments, as well as the potential for cell therapy to offer a biologic, non-opioid alternative to patients suffering from the condition. Finally, we present an overview of an investigational cell therapy called IDCT (Injectable Discogenic Cell Therapy), which is currently under evaluation in multiple double-blind clinical trials overseen by major regulatory agencies. The active ingredient in IDCT is a novel allogeneic cell population known as Discogenic Cells. These cells, which are derived from intervertebral disc tissue, have been shown to possess both regenerative and immunomodulatory properties. Cell therapies have unique properties that may ultimately lead to decreased pain and improved function, as well as curb the numbers of patients pursuing opioids. Their efficacy is best assessed in rigorous double-blinded and placebo-controlled clinical studies. Frontiers Media S.A. 2020-12-16 /pmc/articles/PMC7772215/ /pubmed/33392242 http://dx.doi.org/10.3389/fsurg.2020.554382 Text en Copyright © 2020 Silverman, Heaton, Farhang, Saxon, Dulatova, Rodriguez-Granrose, Flanagan and Foley. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Surgery
Silverman, Lara Ionescu
Heaton, Will
Farhang, Niloofar
Saxon, Lindsey Hart
Dulatova, Galina
Rodriguez-Granrose, Daniel
Flanagan, Flagg
Foley, Kevin T.
Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy
title Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy
title_full Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy
title_fullStr Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy
title_full_unstemmed Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy
title_short Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy
title_sort perspectives on the treatment of lumbar disc degeneration: the value proposition for a cell-based therapy, immunomodulatory properties of discogenic cells and the associated clinical evaluation strategy
topic Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772215/
https://www.ncbi.nlm.nih.gov/pubmed/33392242
http://dx.doi.org/10.3389/fsurg.2020.554382
work_keys_str_mv AT silvermanlaraionescu perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy
AT heatonwill perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy
AT farhangniloofar perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy
AT saxonlindseyhart perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy
AT dulatovagalina perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy
AT rodriguezgranrosedaniel perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy
AT flanaganflagg perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy
AT foleykevint perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy